A Convenient Method for Synthesis of Novel 3-(1,3,4-Oxadiazol-2-yl)-methylene-2-oxo-1,2,3,4-tetrahydro-quinoxalines: Regioselective Cyclization of 3-Ethoxy-hydrazonocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline

Yoshihisa KURASAWA*, Yujiro MORITAKI, Atsushi TAKADA

School of Pharmaceutical Sciences, Kitasato University, Shirokane Minato-ku, Tokyo 108, Japan

Ainsworth¹ reported a simple and general method for the pre paration of various 2-aryl- and 2-alkyl-5-aryl-1,3,4-oxadia zoles (3) by refluxing of acylhydrazides (1) in orthoesters.

$$\begin{array}{c} 0 \\ 1 \\ R^{1}-C-NH-NH_{2} \end{array} \xrightarrow{R^{2}-C(OC_{2}H_{5})_{3}} R^{1}-C-NH-N=C_{3}^{OC_{2}H_{5}} \\ 1 \\ 2 \\ 3a R^{1} = C_{6}H_{5} \cdot R^{2} = H_{3} \cdot R^{2} = CH_{3} \cdot R^{2} = CH_{3$$

However, this method is inconvenient when the intermediary N-acylhydrazonic esters (2) are insoluble in the orthoesters at their reflux temperatures. In fact, our novel N-acylhydrazonic esters (6) are insoluble in refluxing orthoesters, and their cyclizations to 1,3,4-oxadiazoles (7) cannot be accomplished despite prolonged reaction time. However, this problem was solved by refluxing of the insoluble N-acylhydrazonic esters 6 in n-butanol in the presence of a base such as 1,8-diazabicyclo[5.4.0]-7-undecene (DBU). This method enabled us to prepare novel 1,3,4-oxadiazole derivatives, and it was further found that the method effected the cyclization of 2 to 3 within 1 h.

3-Methoxycarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (4) hardly reacts with most amines or an equimolar to 5-fold molar amount of hydrazines². In the present investigation, however, 4 is found to be converted easily to 3-hydrazinocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (5) in the presence of 10-fold molar amount of hydrazine hydrate. Reactions of 5 with triethyl orthoformate and triethyl orthoacetate afford 3-ethoxyhydrazonocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (6a) and 3-methylethoxyhydrazonocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (6b), respectively, which are cyclized to 3-(1,3,4-oxadiazol-2yl)-methylene-2-oxo-1,2,3,4-tetrahydroguinoxaline (7a) and 3-(5-methyl-1,3,4-oxadiazol-2-yl)-methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (7b), respectively, by heating under reflux in n-butanol in the presence of DBU. In contrast, the cyclization to compounds 7a, b is not completed by heating of 6a, b under reflux in the orthoesters. The reaction of 7a, b with N-

aR2 = H; b R2 = CH3

bromosuccinimide affords 4-bromo-3-(1,3,4-oxadiazol-2-yl)-methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (8a) and 4-bromo-3-(5-methyl-1,3,4-oxadiazol-2-yl)-methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (8b), respectively³. The analytical and spectral data (Table) are in accord with the proposed structures of 7a, 7b, 8a, and 8b.

As shown by ¹H-N.M.R. spectrometry, the ester 4 exhibits a tautomeric equilibrium between the forms A and B in DMSO- d_6 solution⁴. Similarly, compounds 5, 7a, and 7b exist as tautomeric pairs in DMSO- d_6 , which are characterized by vinyl and methylene proton signals, respectively (Table).

A

$$\begin{array}{c}
H & X \\
N & C \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H & X \\
N & C
\end{array}$$

$$\begin{array}{c}
H$$

When compound **6a** is heated in dimethylformamide instead of *n*-butanol/DBU, 3-(5-oxopyrazolin-4-yl)-2-oxo-1,2-dihydroquinoxaline **(9)**² results as the cyclization product. Presumably, due to steric hindrance by the methyl group, this cyclization route cannot be realized in **6b**. Thus, heating of **6b** in dimethylformamide results in the formation of **7b** in 60% yield.

3-Hydrazinocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (5):

A solution of compound 4 (10 g, 45.9 mmol) with hydrazine hydrate (22.95 g, 45.9 mmol) in ethanol (200 ml) is refluxed for 3 h on a boiling water bath to precipitate colorless needles of 5, which are collected by suction filtration (9.07 g). Evaporation of the filtrate gives additional product 5 (0.73 g); total yield: 9.80 g (98%). An analytically pure sample is obtained by washing with hot ethanol a few times.

3-Ethoxyhydrazonocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxalines (6); General Procedure:

A solution of 5 (5 g, 22.9 mmol) with the appropriate orthoester (50 ml) in ethanol (700 ml) is refluxed for 3 h on a boiling water bath. When triethyl orthoformate is used, the solvent is evaporated to afford yellow needles of 6a, which are treated with hexane/ethanol and collected by suction filtration; yield: 6.18 g (98%).

When triethyl orthoacetate is employed, yellow needles of **6b** precipitate during the reaction. The needles are collected by suction filtration (5.53 g), and the filtrate is evaporated to provide additional product **6b** (0.93 g); total yield: 6.46 g (98%).

Analytically pure samples of **6a** and **6b** were obtained by washing with hot ethanol a few times.

3-(1,3,4-Oxadiazol-2-yl)-methylene-2-oxo-1,2,3,4-tetrahydroquinoxalines (7):

Method A: A solution of **6a** or **6b** (5 g) with DBU (5 ml) in *n*-butanol (500 ml) is refluxed for 20 h in an oil bath at 160~180 °C. The sol-

Table. Analytical and Spectral Data for Compounds 5, 6a, b, 7a, b, 8a, b

Prod- uct	m.p. [°C] ^a 264–265°	Molecular formula ^b $C_{10}H_{10}N_4O_2$ (218.2)	I.R. (KBr) v [cm ¹] 1665, 1630	¹ H-N.M.R. (DMSO-d ₆) δ [ppm] 11.67 (s, 1H); 11.40 (s, 1H); 9.13 (s, 1H); 7.83-6.70 (m, 4 H _{arom}); 5.60 (s) ^c ; 4.33 (br. s 2 H); 3.66 (s) ^c			
5							
6a	213-214°	$C_{13}H_{14}N_4O_3$ (274.3)	1690, 1630				
6b	248-249°	C ₁₄ H ₁₆ N ₄ O ₃ (288.3)	1690, 1630	d			
7a	290-292°	$C_{11}H_8N_4O_2$ (228.2)	1695, 1640	11.67 (s, 1 H); 10.57 (s, 1 H); 9.13 (s, 1 H); 7.80-6.87 (m, 4 H _{arcm}); 6.12 (s) ^e , 4.47 (s) ^e			
7b	255-256°	$C_{12}H_{10}N_4O_2$ (242.2)	1695, 1640	11.67 (s, 1 H); 10.43 (s, 1 H); 7.77-6.83 (m, 4 H_{arom}); 6.02 (s) ^{f} ; 4.37 (s) ^{f} ; 2.50 (s, 3 H)			
8a	223-224°	$C_{11}H_7BrN_4O_2$ (307.1)	1670	12.83 (s, 1 H); 9.40 (s, 1 H); 7.90-7.10 (m, 4 H _{arom}); 6.90 (s, 1 H)			
8b	214-216°	$C_{12}H_9BrN_4O_2$ (321.2)	1670	12.82 (s, 1 H); 7.90-7.20 (m, 4 H _{erom}); 6.83 (s, 1 H); 2.55 (s, 3 H)			

^a All m.p. are uncorrected.

vent is evaporated to give an oily substance which is dissolved in chloroform/ethanol (10:1) to precipitate the crystalline product **7a** or **7b**. After the product has been collected by suction filtration, the filtrate is passed through a silica gel column using the same mixture as eluent. The eluate is evaporated to afford additional product **7a** or **7b**; total yields: 3.80 g (91%) of **7a**; 3.85 g (91%) of **7b**. Recrystallization from ethanol provides yellow needles of **7a** and **7b**.

Method B: A solution of **6b** (3 g) in dimethylformamide (300 ml) is refluxed for 20 h in an oil bath at 160–180 °C. Evaporation of the solvent and column chromatography as described above gives **7b**; yield: 1.52 g (60%).

4-Bromo-3-(1,3,4-oxadiazol-2-yl)-methylene-2-oxo-1,2,3,4-tetrahydro-quinoxalines (8); General Procedure:

A suspension of 7a or 7b (1 g) with N-bromosuccinimide (1.2 eq.) in tetrachloromethane (100 ml) is refluxed for 4 h on a boiling water bath to precipitate colorless crystals of 8a or 8b, which are collected by suction filtration. The crystals of 8a or 8b are taken up in ethanol by heating, and the solution is immediately filtered. Evaporation of the filtrate gives analytically pure sample of 8a or 8b; yields: 1 g (74%) of 8a; 1 g (80%) of 8b.

3-(Pyrazolin-5-on-4-yl)-2-oxo-1,2-dihydroquinoxaline (9):

A solution of **6a** (3 g) in dimethylformamide (300 ml) is refluxed for 20 h in an oil bath at 160–180 °C. Evaporation of the solvent gives the crystalline product **9**, which is treated with hexane/ethanol to leave a yellow powder; yield: 2.15 g (86%); m.p. 305 °C (Ref.², m.p. 305 °C).

2-Phenyl-1,3,4-oxadiazole (3a) and 2-Methyl-5-phenyl-1,3,4-oxadiazole (3b):

A solution of appropriate N-acylhydrazonic ester $2a^5$ or $2b^5$ (3 g) in n-butanol (300 ml) and DBU (3 ml) is refluxed for 1 h in an oil bath at 160-180 °C. Evaporation of the solvent gives an oily residue, which is dissolved in chloroform. After washing with water (2 × 150 ml) two times to exclude DBU and drying with sodium sulfate, evaporation of the solvent affords the crystalline products 3a and b, respectively.

3a: yield 1.70 g (77%); m.p. 36-37 °C (Ref.¹, m.p. 34-35 °C) **3b:** yield 2.04 g (90%); m.p. 66-68 °C (Ref.¹, m.p. 67-68 °C)

Received: July 12, 1982 (Revised form: October 19, 1982)

Satisfactory mass spectral and microanalytical data were obtained: C, ± 0.3 ; H, ± 0.3 ; N, ± 0.3 .

Vinyl and methylene signal in the ratio 1:1.

d Insoluble in DMSO-d₆.

e Vinyl and methylene signal in the ratio 3.75:1.

Vinyl and methylene signal in the ratio 3:1.

^{*} Address for correspondence.

C. Ainsworth, J. Am. Chem. Soc. 77, 1148 (1955).

² Y. Kurasawa, A. Takada, Chem. Pharm. Bull. 29, 2871 (1981).

³ The bromination at N-4 has been confirmed; unpublished data by the authors.

⁴ R. Mondelli, L. Merlini, Tetrahedron 22, 3253 (1966).

⁵ C. Runti, L. Sindellari, C. Nisi, Ann. Chim. (Rome) 49, 1649 (1959).

F. Babudri, L. Di Nunno, S. Florio, Synthesis 1983 (3), 230-231:

The title compounds **5** and **7** should be named (*Z*)-2-alkylidene-4-methyl-3-oxo-2,3-dihydro-4*H*-1,4-benzothiazines; compound **10** as 11-methyl-3-(2-methylaminophenylthio)-2-oxo-4,5-diphenyl-2,5-dihydro-11*H*-oxepino[3,2-*b*][1,4]benzothiazine.

Y. Kurasawa, Y. Moritaki, A. Takada, Synthesis 1983 (3), 238-240:

The title compounds 6 and 7 should be named 3-(1-ethoxyalkylidene-hydrazinocarbonylmethylene)-2-oxo-1,2,3,4-tetrahydroquinoxalines and 3-(1,3,4-oxadiazol-2-ylmethylene)-2-oxo-1,2,3,4-tetrahydroquinoxalines, respectively.

Abstract 6589, Synthesis 1983 (3), 247:

The title should be N-(1-Aroyloxyalkyl)-pyridinium and P-(1-Aroyloxyalkyl)-phosphonium Salts.

Abstract 6593, Synthesis 1983 (4), 335:

The formula scheme $1 + 2 \longrightarrow 3$ should be:

OH OH
$$R^{1}-CH-C-R^{2} + S=C$$

$$CI$$

$$R^{1}-CH-C-R^{2}$$

$$R^{3}$$

$$R^{3}$$

$$R^{4}-CH-C-R^{2}$$

$$R^{2}-CH-C-R^{2}$$

$$R^{3}-CH-C-R^{2}$$

Y. Otsuji, S. Nakanishi, N. Ohmura, K. Mizuno, Synthesis 1983 (5), 390.

The substituents for compound 2g (Table) should be R=H, X=H, n=1.

Y. Kurasawa, M. Ichikawa, A. Sakakura, A. Takada, Synthesis 1983 (5), 399-400:

The structures of products 4, 8, 9, and 10 given have since been found to be erroneous, the corrected structures are given below. A revision will be published in *Chem. Pharm. Bull.* in 1984.

C. Santelli-Rouvier, M. Santelli, Synthesis 1983 (6), 429-442:

The structure of the third product in Table 4 (p. 435) should be:

S. M. Fahmy, R. M. Mohareb, Synthesis 1983 (6), 478-480:

The structure of product 5 should be:

$$\begin{array}{c|c}
H_2N & C = C \\
\hline
COOC_2H_5
\end{array}$$

L. Jacob, M. Julia, B. Pfeiffer, C. Rolando, *Synthesis* **1983** (6), 451-452:

The first three entries in Table 1 (p. 451) should be as follows:

Table 1. Demethylation of Mixed Alkyl Methyl Phosphates (1, 3, 4) and of Dimethyl Heptanephosphonate (5) using Dimethyl Sulfide (2.5 equiv) and Methanesulfonic Acid (10 equiv)

Substrate	Product	Reaction conditions		Yield ^a	m.p. [°C] ^b	Molecular formula
		Scale [mmol]	Time [h]	- [%]	(solvent)	or m.p. [°C] reported
1a n-C ₆ H ₁₃ -O-P OCH ₃		10	22	82 (93)	133–134° (ethanol)	C ₁₂ H ₂₂ NO₄P (275.3)
1b n-C ₈ H ₁₇ -O-P OCH ₃	2 b • H ₂ N-C ₈ H ₅	5 5 5	7 12 48	(88) (93) (98)	135-137° (acetone)	129–130° ²² (ethanol)
0		5 10 10	19 92 52°	65 83 83		
1c n-C ₆ H ₁₃ -CH-O-P OCH ₃	2 c · H ₂ N-C ₆ H ₅	5 10	19 92	68 79	154° (ethanol)	C ₁₄ H ₂₆ NO ₄ P (303.3)